Testing FMC-376 for KRAS G12C mutated solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer with a specific change in your DNA called a KRAS G12C mutation.
- You must have tried at least one standard treatment that either stopped working or caused side effects you couldn't handle.
- You should be feeling well enough to carry out daily activities, like walking or doing light housework.
- Your blood counts, kidney function, and liver function must be in a safe range.
- You cannot have any other serious medical condition that would make the study risky for you.
- You must agree not to join any other research study while taking part in this one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This study tests a new drug called KQB368 for advanced solid cancers that have a specific genetic change (KRAS G12C or G12S mutation). The drug is designed to target this mutation and may help slow or shrink tumors in patients who don't have other curative treatment options.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.